HCR040 / Noray - LARVOL DELTA

Lung microbiome and clinical outcomes during antibiotic treatment of CF pulmonary exacerbations: Insights from the STOP2 trial (NACFC 2025) - "Pa ent ID Early Morning Cough Clear (emCC) Home sputum-induc on (hIS) Clinic Cough Swab (CS) Clinic Couch Clear (cCC) Clinic sputum-induc on (cSI) HCF005 S. aureus S. aureus HCF011 P. aeruginosa P. aeruginosa P. aeruginosa P. aeruginosa P. aeruginosa HCF014 P. aeruginosa P. aeruginosa, H. influenzae H. influenzae P. aeruginosa, H. influenzae P. aeruginosa, H. influenzae HCF015 S. aureus S. aureus S. aureus HCF016 H. influenzae HCF017 S. aureus S. aureus HCF018 S. aureus S. aureus S. aureus S. aureus S. aureus HCF029 H. influenzae H. influenzae HCF034 P. aeruginosa, S. aureus HCF039 NTM HCF041 S. aureus S. aureus HCF043 P. aeruginosa P. aeruginosa P. aeruginosa HCF045 S. aureus S. aureus S. aureus HCF048 S. aureus, S. maltophilia, K. oxytoca S. aureus, S. maltophilia S. aureus S. aureus HCF049 A. baumanii HCF055 H. influenzae HCF057 S. aureus S. aureus HCF058 S. aureus S. aureus S. aureus HCF059 H. influenzae H. influenzae H. influenzae HCF061 P. aeruginosa P. aeruginosa..."

Clinical • Clinical data • Lung Microbiome • Cough • Cystic Fibrosis • Genetic Disorders • Immunology • Infectious Disease • Influenza • Respiratory Diseases

Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1/2 | N=26 | Completed | Sponsor: Histocell, S.L. | Recruiting ➔ Completed

Trial completion • Acute Respiratory Distress Syndrome • Pulmonary Disease • Respiratory Diseases

Conditioned Medium from HO-Preconditioned Human Adipose-Derived Stem Cells Ameliorates UVB-Induced Damage to Human Dermal Fibroblasts. (PubMed, Antioxidants (Basel)) - "Further, HC016-CM treatment increased viability, migratory capacity and collagen type I synthesis in hFFs exposed to UVB radiation, as well as reducing their cytotoxicity, apoptosis, senescence and IL-6 secretion. Collectively, these findings support the view that HC016 cells could protect against UVB-induced photodamage via paracrine mechanisms."

Journal • IL6

SPINE: Safety and Preliminary Efficacy of FAB117-HC in Patients With Acute Traumatic Spinal Cord Injury (clinicaltrials.gov) - P1/2; N=48; Recruiting; Sponsor: Ferrer Internacional S.A.; Trial completion date: Mar 2022 ➔ Jul 2023; Trial primary completion date: Oct 2021 ➔ Jul 2022

Clinical • Trial completion date • Trial primary completion date • CNS Disorders • Orthopedics • MRI

Hydrogen Peroxide-Preconditioned Human Adipose-Derived Stem Cells Enhance the Recovery of Oligodendrocyte-Like Cells after Oxidative Stress-Induced Damage. (PubMed, Int J Mol Sci) - "The results demonstrated that both strategies had reparative effects, oxidized HC016 cell co-culture being the one associated with the greatest recovery of the damaged HOGd, increasing their viability, reducing their intracellular reactive oxygen species levels and promoting their antioxidant capacity. Taken together, these findings support the view that HC016 cells, given their reparative capacity, might be considered an important breakthrough in cell-based therapies."

Journal • CNS Disorders • Immunology • Inflammation • Solid Tumor

Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1/2; N=26; Recruiting; Sponsor: Histocell, S.L.; Active, not recruiting ➔ Recruiting

Clinical • Enrollment open • Acute Respiratory Distress Syndrome • Respiratory Diseases

HO-preconditioned human adipose-derived stem cells (HC016) increase their resistance to oxidative stress by overexpressing Nrf2 and bioenergetic adaptation. (PubMed, Stem Cell Res Ther) - "HO preconditioning enhances hASC survival under oxidative stress conditions by stimulating their antioxidant response and bioenergetic adaptation. Therefore, this preconditioning strategy might be considered an excellent tool for strengthening the resistance of hASCs to harmful oxidative stress."

Journal • Immunology • Transplantation • GPX1

Clinical Study to Assess the Safety and Preliminary Efficacy of HCR040 in Acute Respiratory Distress Syndrome (clinicaltrials.gov) - P1/2; N=26; Active, not recruiting; Sponsor: Histocell, S.L.

Clinical • New P1/2 trial